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Mercaptopurine is a purine antagonist, belonging to the class of antimetabolites. Its oral absorption is 
erratic and variable throughout GIT, with bioavailability of 5-37% and belongs to Biopharmaceutical 
Classification System (BCS) class IV. The focus of the present study was to improve solubility of 
mercaptopurine and to release the drug uniformly throughout the GIT by formulating into a novel in situ 
gel tablet. By in vitro swelling studies, xanthan gum was selected as the best gelling polymer and the 
tablets were prepared by direct compression. Sodium chloride was used as a release modifier to improve 
the release of drug from the tablet. A 32 full factorial design was applied to optimize the percentage of 
xanthan gum and sodium chloride to get desired swelling index and release profile. Tablets were evaluated 
for weight variation, hardness, friability, disintegration time, drug content, in vitro swelling studies and 
in vitro dissolution studies. The best optimized formulation showed good swelling index and extended 
the release up to 12 h, where as conventional tablet released the drug within 45 min. The results indicate 
that mercaptopurine loaded in situ gel tablet could be effective in sustaining drug release for a prolonged 
period of time throughout the GIT, which can possibly improve the oral bioavailability.
Uniterms: Mercaptopurine/solubility. Mercaptopurine/drug delivery. Xanthan gum/use. Tablets/in situ 
gel.
Mercaptopurine é um antagonista da purina, pertencente à a classe dos antimetabólitos. A sua absorção oral 
é errática e variável através do TGI, com biodisponibilidade de 5-37 % e pertence à classe IV, de acordo 
com o Sistema de Classificação Biofarmacêutica. O foco do presente estudo foi melhorar a solubilidade 
da mercaptopurina e liberar o fármaco uniformemente através do TGI, por meio da nova formulação 
de comprimidos que se tornam gel in situ. Por meio de estudos de inchamento, a goma xantana foi 
selecionada como o o melhor polímero gelificante e os comprimidos foram preparados por compressão 
direta. O cloreto de sódio também foi usado como agente modificador de liberação para aprimorar a 
liberação do fármaco do comprimido. Aplicou-se planejamento fatorial 32 para otimizar a porcentagem 
de goma xantana e de cloreto de sódio para se alcançar o índice de inchamento e o perfil de liberação 
desejáveis. Os comprimidos foram avaliados quanto à variação de peso, dureza, friabilidade, tempo de 
desintegração, conteúdo de fármaco, estudos in vitro de inchamento e de dissolução. A formulação mais 
bem otimizada mostrou bom índice de inchamento e liberação prolongada acima de 12 h, em comparação 
com um comprimido convencional, que libera o fármaco em 45 minutos. Os resultados indicam que 
a 6-mercaptopurina carregada no comprimido de gelificação in situ poderia ser eficaz para a liberação 
controlada por período de tempo prolongado através do TGI, o que pode, possivelmente, aprimorar a 
biodisponibilidade oral. 
Unitermos: Mercaptopurina/solubilidade. Mercaptopurina/liberação do fármaco. Goma xantana/uso. 
Comprimidos/gelificados in situ.
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INTRODUCTION
Mercaptopurine (6-MP) is a highly insoluble purine 
antagonist and belongs to the class of antimetabolites 
and is well known for its antitumor activity. It belongs to 
BCS class IV (poor solubility and poor permeability). The 
drug is used to treat leukemia, paediatric non-Hodgkin’s 
lymphoma, Polycythemia Vera and Inflammatory Bowel 
Disease (such as Crohn’s disease and ulcerative colitis). 
The oral absorption of 6-MP is erratic with only 10–50% 
of the administered dose reaches the systemic circulation. 
The limiting factors in the use of 6-MP are its very short 
half-life in plasma (0.5-1.5 h) and variable bioavailability 
(about 5-37%) (Zacchigna et al., 2007).
By formulating into sustained release (SR) dosage 
form the above potential problems associated with drug 
can be overcome (Singh et al., 2012). The most commonly 
used method for fabricating drugs in a SR formulation is by 
incorporating them into a matrix containing a hydrophilic 
rate-controlling polymer. Matrix systems are widely used in 
oral controlled drug delivery because of their simplicity in 
manufacturing processes, level of reproducibility, stability 
of the raw materials and dosage form (Gennaro, 2000).
In situ gel forming tablets are a revolution in oral 
drug delivery. Gel-forming tablets provide a popular and 
convenient SR dosage form for delivering drugs over an 
extended time for 8-24 h (Laity et al., 2010). The drug is 
dispersed within a polymeric matrix, which controls the 
release rate. On contact with water or body fluids the outer 
surface of these tablets swell by polymer hydration and 
chain relaxation, forming a hydrogel coat (Parka et al., 
2010; Baumgartner et al., 2005). When a poorly water 
soluble drug is dispersed throughout such a polymeric 
matrix, the swelling mechanism of the polymer results in 
wetting of the drug, due to sufficient contact between the 
drug and medium and thus enhancing the solubility of the 
drug (Ishikawa et al., 2000).
Many synthetic, semi synthetic and natural 
hydrophilic polymers are used in the formulation of in 
situ gel tablets. The most commonly used are natural 
hydrophilic polymers because they are compatible and 
economical to formulate (Sourabh et al., 2008).
Xanthan gum is a natural and biocompatible anionic 
polyelectrolyte with a semi-rigid chain structure. It is used 
to produce directly compressed matrices that display a 
high degree of swelling due to water uptake. Xanthan gum 
produces strong elastic gel by direct interaction between 
the polymeric chains which controls the drug release. 
Compared to hydroxy propyl methyl cellulose, xanthan 
gum has the potential advantage of drug release with zero 
order release kinetics (Mikac et al., 2010).
The primary aim of the present study was to 
investigate whether it is possible to manufacture in 
situ gelling tablets of mercaptopurine for enhancing 
its solubility and bioavailability. Further the study was 
focused to acquire a comprehensive understanding about 
the influence of formulation parameters that powerfully 
affect the characteristics of the in situ gelling tablets. The 
effect of formulation parameters on swelling index and 
cumulative percentage release (CPR) was studied using 




Mercpatopurine monohydrate was received ex-
gratis by M/S Dabur Pharmaceuticals Ltd, Ghaziabad, 
India. Xanthan fum, sodium alginate and hydroxypropyl 
cellulose (HPC) were purchased from M/S SD fine-
chemicals limited (Mumbai, India). Hydroxy propyl 
methylcellulose (HPMC E15-LV) was provided ex-gratis 
by Himedia, Mumbai. PEG-6000 was received ex-gratis 
by M/S Titan Biotech. Sodium chloride was purchased 
from M/S Reachem Laboratory Chemicals. All other 
chemicals used were of analytical grade. 
Formulation of in situ gel tablet of 
mercaptopurine
To select the most suitable polymer preliminary 
screening studies were carried out by preparing placebo 
tablets. The placebo tablets were prepared with xanthan 
gum (Mikac et al., 2010), sodium alginate (Miyazaki et 
al., 1995), HPMC (Vazquez et al., 1996), HPC and Poly 
Ethylene Glycol-6000. The formulation of preliminary trial 
batches P-1 to P-10 are shown in Table I. The tablets were 
evaluated for hardness, disintegration time, swelling index.
Evaluation of placebo tablets
The placebo tablets were evaluated for hardness, 
disintegration time and in-vitro swelling studies. 
Hardness
Tablets require a certain amount of strength or 
hardness to withstand mechanical shocks due to handling 
in manufacturing, packing and shipping. For each 
formulation, the hardness of 6 tablets was determined 
using the Monsanto hardness tester. The average hardness 
was calculated and recorded as kg/cm2.
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TABLE I - Placebo tablets prepared for screening of polymers
Excipients ( %) P1 P2 P3 P4 P5 P6 P7 P8 P9 P10
Xanthan gum Sodium alginate HPMC HPC PEG 6000
Polymer 50 75 50 80 30 80 20 40 45 80
Talc 5 5 5 5 5 5 5 5 5 5
Mg. Stearate 1 1 1 1 1 1 1 1 1 1
MCC Quantity sufficient to make 150 mg tablet
*The minimum and maximum percentage of each polymer selected in the above formulations was based on the reported literature.
TABLE II - Batches prepared for selection of suitable diluent
Ingredients (mg/tab) F1 F2 F3
Mercaptopurine 50 50 50
Xanthan gum 75 75 75
Talc 7.5 7.5 7.5
Magnesium stearate 1.5 1.5 1.5
Spray dried lactose - 8 16
MCC 16 8 -
Disintegration time
Disintegration time of the formulations was 
determined using Electrolab disintegration test apparatus. 
Six tablets were placed individually in each tube of 
disintegration test apparatus and discs were placed on it. 
Apparatus was operated using pH 1.2 buffer as medium, 
maintained at 37 ± 2 °C. The time required for complete 
disintegration of the tablets was recorded.
In vitro swelling studies
In vitro swelling studies were performed using USP 
apparatus of basket type at 37±0.5 oC and rotational speed 
of 50 rpm. The tablet from each batch was kept in basket 
placed in dissolution flask and initial dry weight of basket 
(Mo) was recorded. The basket was placed in 900 mL of 
pH 1.2 buffer, for first 2 h. After specific time intervals 
30 min, 60 min and 120 min the basket was taken out and 
weight of basket (Mt) was recorded after blotting with 
tissue paper. Again basket was placed in dissolution flask 
containing 900 mL of pH 7.4 phosphate buffer and stirring 
was carried out at 50 rpm. The basket was withdrawn at 
specific time intervals of 1 h and weighed for next 10 h 
(Babu et al., 2002).
From equation [1] the percentage weight gain by 
the tablet was calculated using the formula (Deshmukh 
et al., 2009):
   (1)
where, SI = Swelling index, Mt = Weight of tablet at time‘t’ 
and Mo = Weight of tablet at time ‘0’.
Formulation of in-situ gel tablets of 
mercaptopurine with xanthan gum
Mercaptopurine tablets were prepared by mixing 
the drug with xanthan gum, where talc, and magnesium 
stearate were used as glidant and lubricant, respectively. 
The formulations F-1 to F-3 were prepared to select the 
most suitable diluent (Table II). Spray dried lactose and 
MCC either alone or in combination were used as diluents. 
The powder blends was passed through sieve no 40 and 
then the tablets were compressed by direct compression 
method using tablet compression machine (CIP Punching 
Machineries Pvt. Ltd, Mumbai, India) with 8 mm round 
punch. The tablets were evaluated. 
 
Evaluation of tablets
The directly compressed tablets from formulation 
F-1 to F-3 were evaluated for parameters viz., weight 
variation, hardness, friability, disintegration time, drug 
content, in-vitro swelling studies and in-vitro drug release 
studies.
 
Weight variation test 
The test was performed according to Indian 
Pharmacopeial norms. Twenty tablets were weighed 
individually and average weight was calculated. The 
individual weights were then compared with average 
weight. The weight variation was calculated as follows:
 
where, PD= Percentage Deviation Wavg = Average Weight 
of Tablet Wind = Individual Weight of Tablet.
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Hardness
The experimental method described above was used 
to determine the hardness of formulations F-1 to F-3. 
Friability
The friability of 10 tablets was determined according 
to US Pharmacopeia using Electrolab (EF2) Friabilator. 
The friabilator was operated at 25 rpm for 4 minutes or run 
up to 100 revolutions to know the mechanical strength of 
the tablet while handling, packing and shipping. 
Disintegration time
The experimental method described above was used 
to determine the disintegration time for formulations F-1 
to F-3.
Drug content
10 tablets were crushed and powdered blend 
equivalent to 50 mg of mercaptopurine was weighed and 
dissolved in in 0.1 N NaOH. From this 10 mL was pipetted 
out into a 100 mL volumetric flask and volume was made 
up to 100 mL with 0.1N NaOH. Absorbance was measured 
at 311 nm using UV spectrophotometer. Drug content was 
determined from calibration curve. The experiment was 
carried out in triplicate. 
In vitro swelling studies
The experimental method described above was used 
to determine in-vitro swelling studies for formulations 
F-1 to F-3.
Optimization of percentage of polymer and 
release modifier by 32 factorial design
To optimize the percentage of polymer and release 
modifier 32 full factorial design was applied. In this design 
2 factors were evaluated, each at 3 levels, and experimental 
trials were performed at all 9 possible combinations. The 
percentage of xanthan gum (X1) and release modifier 
(X2) were selected as independent variables. Swelling 
index and CPR were the dependent variables. Checkpoint 
batches were also prepared to prove the validity of the 
evolved mathematical model (Devi et al., 2009; Singh et 
al., 2012). Further, mercaptopurine tablets were prepared 
and the formulations were coded as F-4 to F-12. These 
formulations were prepared by varying percentage of 
xanthan gum (50%, 40% and 30%) along with sodium 
chloride in 5%, 7.5% and 10%, respectively as release 
modifier. (Table III). The level and coded variables are 
shown in Table IV. These tablets were obtained by direct 
compression method as discussed in previous section. 
Step-wise backward linear regression analysis was 
used to develop polynomial equations for the dependent 
variables by using PCP Disso 2000 V3 software. The 
validity of the derived polynomial equations for the 
dependent variables (swelling index and CPR) was 
verified by designing and evaluating two check point 
formulations (C1 and C2) Table IV. 
A statistical model incorporating interactive and 
polynomial terms was utilized to evaluate the (Equation 2).
Y = b0 + b1X1 + b2X2 + b12X1X2 + b11X12 + b22 X22 (2)
where Y is dependent variable; X1, X2 are the levels 
(concentration) of the 1, 2 factor; b1, b2, b12, b11, b22 are the 
polynomial coefficients; b0 is the intercept (which represents 
the response when the level of all factors is low).
The main effects (X1 and X2) represent average 
result of changing one factor at a time from its low to 
high value. The interaction term (X1X2) shows how the 
response changes when two factors are simultaneously 
changed. The polynomial terms (X12 and X22) are included 
to investigate non-linearity.
Evaluation of tablets
The directly compressed tablets from formulation F-4 
to F-12 were evaluated for post-compression parameter like 
TABLE III - Batches prepared for optimization of percentage of polymer and release modifier
Ingredients* (mg/tab) F4 F5 F6 F7 F8 F9  F10 F11  F12
Mercaptopurine 33.3 33.3 33.3 33.3 33.3 33.3 33.3 33.3 33.3 
Xanthan gum 50 50 50 40 40 40 30 30 30
Sodium chloride 5  7.5 10 5  7.5 10 5  7.5 10
Talc 5 5 5 5 5 5 5 5 5
Magnesium stearate 1 1 1 1 1 1 1 1 1
MCC 5.6 3.16 0.66 15.6 13.1 10.6 25.6 23.1 20.6
* Per 150 mg of tablet
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TABLE IV - Factorial design batches of mercaptopurine tablets
Variables F4 F5 F6 F7 F8 F9 F10 F11 F12 C1 C2
X1 -1 -1 -1 0 0 0 +1 +1 +1 -0.5 +0.5 
X2 -1 0 +1 -1 0 +1 -1 0 +1 -0.5 +0.5
weight variation, hardness, friability, disintegration time, 
drug content, in-vitro swelling studies, in-vitro drug release 
studies. Kinetic modeling for drug release was applied. The 
experimental methods described above were carried out. 
Based on the above evaluation, the best formulation F-11 
was selected and further evaluated for compatibility studies 
such as FTIR and DSC analysis. In-Vitro release behavior of 
this formulation was compared with marketed formulation. 
Further the effect of tablet shape and compression force on 
in-vitro release and swelling index of formulation F-11 was 
evaluated. The formulation was subjected to stability studies 
as per ICH guidelines.
Weight variation test 
The weight variation test was carried out as per 
Indian Pharmacopoeial norms. 
Friability
Tablets were tested for friability using Electrolab 
apparatus (EF2) (Patel et al., 2005) following procedure 
described in earlier section. 
Hardness
The experimental method described above was used 
to determine the hardness of formulations F-4 to F-12. 
Drug content 
For drug content determination, 6 tablets were 
randomly selected and crushed. Powdered blend equivalent 
to 50 mg of mercaptopurine was weighed, extracted with 
0.1 N NaOH and analyzed by measuring the absorbance at 
311 nm after suitable dilution, using Shimadzu UV-1601 
UV/Vis double beam spectrophotometer as procedure 
described above. The experiment was carried out in 
triplicate. 
In vitro swelling studies
The experimental method described above was used 
to determine in-vitro swelling index for formulations F-4 
to F-12.
In vitro release studies
In vitro release studies were carried out in Electrolab 
TDT-06PL Dissolution tester USP apparatus Type I 
(rotating basket) at a speed of 50 rpm in 900 mL of 
dissolution medium. Initially for 2 h, the study was carried 
out in simulated gastric fluid pH 1.2 and then medium 
was filtered through Whatmann filter paper. Furthermore, 
the tablet retained on filter paper was transferred to 
dissolution flask and the study was continued up to 
10 h in pH 7.4 phosphate buffer. The temperature was 
retained at 37.0±0.5 °C. 5 mL of samples were withdrawn 
at predetermined intervals and were analyzed by UV 
spectrophotometer at 311nm (Model UV-1700, UV-Visible 
spectrophotometer, Shimadzu, Kyoto, Japan). Based on in 
vitro release studies formulation F-11 was selected as best 
formulation to give a SR effect for 12 h. 
Comparison of in-vitro release studies of F-11 
with marketed formulation
In vitro dissolution studies were performed for 
marketed (MKT) formulation of mercaptopurine 
(conventional tablet) using Electro lab-USP Dissolution 
test apparatus of paddle type with RPM of 50. Simulated 
gastric fluid pH 1.2 was the dissolution medium. 
Temperature of 37±0.1 oC was maintained. 5 mL of sample 
was withdrawn at 5, 10, 15, 20, 30 and 45 min and was 
replaced with 5ml of pH 1.2 buffer after each withdrawl. 
5 mL withdrawn sample was filtered. 1 mL of filtrate was 
diluted to 10 mL using 0.1 N NaOH. The dissolution data 
of formulation F-11 obtained was compared with the data 
of MKT formulation. Absorbance was measured at 311 nm 
using UV spectrophotometer. 
Kinetic modeling of drug release
The dissolution profile of all the batches was fitted 
to first-order, zero-order, Higuchi matrix, Hixon-Crowell, 
Korsmeyer and Peppas to ascertain the kinetic modeling 
of drug release by using PCP Disso Version 2.08 software, 
and the model with the highest correlation coefficient was 
considered to be the best model.
Differential scanning calorimetry
Differential scanning calorimetry (DSC) studies were 
conducted using DSC Q2000. Sample was weighed (8.00-
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10.00±0.5 mg) and placed in sealed aluminum pans. The 
coolant was liquid nitrogen. The samples were scanned at 
100 ºC/min from 200 to 350 ºC. DSC thermo grams of pure 
drug, physical mixture and final formulation were taken.
Powder X-ray diffraction
Powder X-ray diffraction (PXRD) of pure drug, 
physical mixture and final formulation were recorded 
using a Philips PW 1729 X-ray diffractometer with 
monocrotized Cu Ka radiation, at a speed of 2θ min-1 
from 100-600 2θ under the voltage and current of 40 Kv 
and 30 Kv.
Effect of tablet shape and compression force on 
in-vitro release and swelling for formulation F-11
The optimized formulation was prepared to study 
the effect of tablet shape and compression force on in-
vitro release and swelling index. The powder blend was 
compressed on Rimek MINI PRESS-II SF (Karnavati) 
using oval punch size of 9.4 x 5.6 mm under different 
compression forces at 2000 kg (2 kg/cm2), 3000 kg 
(3 kg/cm2), 4000 kg (4 kg/cm2) and 5000 kg (5 kg/cm2).
In vitro swelling studies 
The experimental method described above was used 
for formulations F-11. 
In vitro release studies 
The experimental method described above was used 
for formulations F-11.
Stability studies
Stability testing is an integral part of formulation 
development. Stability study of the optimized matrix 
tablets was carried out as per ICH guidelines at 
40±2 °C/75%±5% RH. Physical attributes of the tablets, 
appearance, percentage drug content and dissolution 
profiles were tested over a period of 3 months.
RESULTS AND DISCUSSION
Screening of suitable gelling polymer for 
preparation of in situ gel tablet
The placebo tablets containing xanthan gum 
exhibited best hardness, swelling index and disintegration 
time as shown in Tablet V, whereas tablets containing 
PEG-6000 showed least hardness, disintegration time 
and negligible swelling. Thus xanthan gum was selected 
as the best in-situ gelling polymer for the preparation of 
6-mercpatopurine tablets.
Evaluation of mercaptopurine tablets
The physicochemical properties of the tablets 
are summarized in Table VI. The formulation F-1 to 
F-12 indicated good physical strength as they exhibited 
excellent hardness ranging from 4.23-5.54 kg/cm2 and also 
low friability values of 0.099-0.245% (Limit - <0.8%), 
weight variation was found to be <7.5% and drug content 
was found to be in range of 99.193-100.60%, which is 
within Pharmacopoeial limit (85-115%).
In vitro swelling studies
Swelling studies were carried out for all formulations 
F-1 to F-12. The swelling index indicates that the quantity 
of water which is absorbed by dissolution medium. The 
changes in weight, characteristic of water uptake and 
swelling, depend on amount of xanthan gum present in 
each formulation. The formulations F-1 to F-3 containing 
50% of xanthan gum showed excellent swelling whereas 
formulations F-4 to F-12 also contains sodium chloride 
as release modifier showed reduced swelling. As the 
percentage of xanthan gum decreases and sodium chloride 
increases, swelling index decreases as shown in Figure 1. 
The photographs of in situ gel tablets are shown in Figure 2.
In vitro release studies
In vitro drug release was determined for the 
formulated tablets and it was compared with marketed 
TABLE V - Hardness, disintegration and swelling index for formulation P-1 to P-10
Evaluation parameters P1 P2 P3 P4 P5 P6 P7 P8 P9 P10
Hardness (kg/cm2) 4.5 5 2.5 1 2 1.5 2.5 3.5 1 2.5
Disintegration Time (min) >120 >120 >120 110 70 90 102 >120 9 10
Swelling Index (%) 906 1679 97 121 56 68 38 41 -  -
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formulation. Figure 3 shows the effect of diluents (MCC 
and spray dried lactose) on release rate of mercaptopurine 
tablets. Formulation F-1 containing MCC alone releases 
the drug faster when compared to F-2 and F-3, containing 
spray dried lactose and their combination. The drug release 
profile of F-1, F-2 and F-3 indicated the need for inclusion 
of a release modifier in the formulation. Sodium chloride in 
the concentration range of 5-10% was chosen as the release 
modifier. The release data obtained for formulations F-4 
to F-12 which were prepared according 32 factorial design 
are given in Table VII and shown in Figure 4. 
The formulation F-4 to F-6 containing 50% xanthan 
gum with 5%, 7.5% and 10% of sodium chloride showed 
percentage drug release of 58.51%, 66.13% and 77.85% 
at the end of 12h. The drug release was found to be less 
in formulation F-4 to F-6. Further formulations F-7 to 
F-9 (40% xanthan gum with 5%, 7.5% and 10% sodium 
chloride) and F-10 to F-12 (30% xanthan gum with 5%, 
7.5% and 10% sodium chloride) were also prepared. F-7 
FIGURE 1 - Comparison of in vitro swelling studies for F-1 to 
F-12.
FIGURE 2 - Photographs of in situ gel tablets a) at 0 hour and 
b) after 6 hours.
and F-8 showed percentage drug release of 75.72% and 
86.13% at 12 h. But F-9 released 91.3% of drug within 
10 h due to loss of tablet integrity at higher sodium 
chloride concentration. F-10 and F-11 showed percentage 
drug release of 88.2% and 95.9% at 12 h. F-12 released 
96.22% of drug at the end of 8h because the tablet started 
eroding after 1 h. As F-11 showed good swelling index 
and could sustain the release till 12 h, and found to be 
optimum when compared with the MKT formulation, 
which released the drug within 45 min (Figure 4). 
TABLE VI - Weight variation, hardness, friability and drug content formulation F-1 to F-12 
Evaluation parameters* F1 F2 F3 F4 F5 F6
Weight variation (% ) 4.76±0.075 3.25±0.081 4.52±0.045 5.21±0.052 4.85±0.081 5.87±0.085
Hardness (kg/cm2) 5.03± 0.208 5.54±0.152 5.33±0.115 5.16±0.152 5.54±0.152 5.38±0.102
Friability (%) 0.093±0.022 0.107±0.263 0.112±0.112 0.204±0.074 0.107±0.263 0.176±0.075
Drug content (%) 99.08±0.04 100.5±0.20 99.86±0.15 100.03±0.23 99.62±0.20 100.60±0.33
Evaluation parameters* F7 F8 F9  F10 F11  F12
Weight variation (% ) 2.48±0.022 3.67±0.038 1.52±0.036 3.56±0.56 1.06±0.59 2.34±0.13
Hardness (kg/cm2) 4.66±0.126 4.54±0.321 4.23±0.235 4.79±0.097 4.83±0.112 4.56±0.145
Friability (%) 0.099±0.025 0.117±0.492 0.111± 0.039 0.196±0.012 0.145±0.112 0.245±0.109
Drug content (%) 99.63±1.78 100.49±0.34 100.12±0.98 99.440±1.19 99.193±0.19 100.36±1.02
*Average of three determinations
N. R, R. S. Pai, G. Singh114
Full factorial design
The formulations were optimized by applying 
32 randomized full factorial design. The percentage of 
xanthan gum (X1) and percentage of release modifier (X2) 
were selected as independent variables. Swelling index 
and CPR were the dependent variables.
From the data of experimental design and parameters 
(Table VII) for factorial formulations F-4 to F-12, 
polynomial equations for two dependent variables 
(swelling index and in vitro release study) were derived 
using PCP Disso 2000V3 software.
The equation derived for swelling index is:
Y1 = 839.36 +159.03 X1 – 186.50 X2 (3)
The equation derived for CPR is:
Y2= 74.835 – 14.887 X1 + 10.04 X2 – 2.765 X1X2 –  
7.390 X12 + 5.781 X22  (4)
TABLE VII - 32 Full factorial design layout
Batch Code
Variable levels in coded forms
Swelling index CPR
X1 X2
F4 +1 -1 1160 51.57
F5 +1 0 1053 48.81
F6 +1 +1 866.6 66.09
F7 0 -1 920 70.18
F8 0 0 889.3 74.59
F9 0 +1 540 91.3
F10 -1 -1 872.2 75.2
F11 -1 0 826.6 83.56
F12 -1 +1 426.6 99.8
C1 -0.5 -0.5 858.9 (853.09)* 74.87 (76.16) *
C2 +0.5 +0.5 821.56 (825.63) * 73.18 (71.32 ) *
Coded values
Actual values (mg)






*Value in parenthesis indicates the predicted values.
FIGURE 3 - Comparison of in-vitro release studies for F-1 to F-3. FIGURE 4 - Comparison of in vitro release studies of optimized 
formulations with MKT formulation.
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In equation (3) negative sign for coefficient of X2 
indicated that as the concentration of release modifier 
increased, swelling index decreases and positive sign for 
coefficient of X1 indicates that an increase in polymer 
concentration increases the swelling index.
In equation (4) negative sign for coefficient of X1 
indicates that an increase in polymer concentration, CPR 
decreases. Positive sign for coefficient of X2 indicates 
that CPR increases with increase in release modifier 
concentration. The negative sign for coefficient of X1X2 
indicates that no significant interaction is observed 
between the 2 factors if they are changed simultaneously.
Response surface plots
Graphical presentation of the data can help to 
show the relationship between response and independent 
variables. Graphs gave information similar to that of the 
mathematical equations obtained from statistical analysis. 
The response surface graphs of swelling index and CPR 
are presented in Figure 5 and Figure 6, respectively.
The response surface plots illustrated that as 
percentage of polymer increases, the swelling index 
increases and CPR decreases but when percentage of 
release modifier increases, swelling index decreases and 
CPR increases. 
Check point formulation
Validity of the equations was verified by designing 
two check point formulations (C1 and C2). The swelling 
index and CPR predicted from the equations derived 
and those observed from experimental results are 
summarized in Table VII. The closeness of predicted and 
observed values for the swelling index and CPR indicates 
FIGURE 5 - Response surface plot showing effect of factorial 
variables on swelling index.
FIGURE 6 - Response surface plot showing effect of factorial 
variables on CPR.
the validity of derived equations for the dependent 
variables.
Kinetic modeling of drug release
The dissolution data of batches F-4 to F-12 was fitted 
to various release kinetic models. Most of the formulation 
batches which follows Zero order release. Table VIII lists 
out the regression parameters obtained after fitting various 
release kinetic models to the in vitro dissolution data. 
The release profile of the best batch, F-11, was ranked in 
the order of Zero order > Korsemeyer-Peppas > Hixson 
Crowell cube root law > Matrix > First order with slope of 
8.013 and R2 value of 0.993. In Zero order, it is assumed 
that the release rate is independent of concentration.
Differential scanning calorimetry
DSC thermograms of pure drug, physical mixture and 
Final optimized formulation F-11 are shown in Figure 7. The 
thermogram of mercaptopurine exhibit single endothermic 
broad peak at 314.4 °C corresponding to the melting 
point of mercaptopurine. In case of physical mixture, the 
drug peak shifted to lower temperature of 305.9 °C with 
reduced intensity which may be due to baseline shift and 
an additional peak at 260 °C was observed due to presence 
of xanthan gum and microcrystalline cellulose (Melting 
point 255 °C–265 °C). Similar peaks were observed for final 
optimized formulation F-11 with increased intensity that 
might have occurred due to punching of tablets. Since there 
was no much difference in the melting point of the drug in 
all the thermographs, it was concluded that, the drug is in 
the same pure state even in the formulation F-11 without 
interacting with the polymers.
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X-ray diffraction studies
Diffraction spectra of pure mercaptopurine, physical 
mixture and formulation F-11 is shown in Figure 8. The 
X-ray pattern of pure mercaptopurine revealed a drug 
fingerprint with intense and sharp peaks, indicating its 
crystalline nature as demonstrated by numerous distinct 
peaks observed at 11.8, 14.6, 16.8, 21.2, 23.6, 25.3, 25.9, 
27.6, 29.5 and 30.4 (2θ). The prominent peaks of pure 
mercaptopurine were clearly seen at the same position 
FIGURE 7 - DSC spectras of a) Pure mercaptopurine b) Physical mixture and c) Formulation F-11.
TABLE VIII - Kinetic modeling of drug release
Formulation




Matrix Zero order First order Hixson Crowell Korsemeyer-Peppas
F4 0.8751 0.9745 0.9389 0.9527 0.9710 0.8183 Zero order
F5 0.8751 0.9722 0.9284 0.9482 0.9473 0.7693 Zero order
F6 0.8765 0.9707 0.9187 0.9414 0.9116 0.7071 Zero order
F7 0.8954 0.9892 0.9430 0.9634 0.9773 0.8992 Zero order
F8 0.9006 0.9899 0.8430 0.9341 0.9759 0.8584 Zero order
F9 0.9064 0.9902 0.7977 0.9032 0.9733 0.7801 Zero order
F10 0.8863 0.9841 0.9196 0.9506 0.9560 0.8900 Zero order
F11 0.9118 0.9936 0.8566 0.9336 0.9785 0.8283 Zero order
F12 0.8927 0.9900 0.8418 0.9215 0.9923 1.1393 Korsemeyer-
Peppas
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FIGURE 8 - XRD spectras of a) Pure mercaptopurine; b) Physical mixture and c) Formulation F-11.
in the physical mixture and in formulation F-11 with 
remarkably decreased intensity. No new peaks were 
observed, suggesting the absence of interaction between 
the drug and the polymer.
Effect of tablet shape and compression force on 
in vitro release and swelling
The change in the tablet shape and compression 
force alters the in vitro swelling and in vitro dissolution 
studies. The swelling index of oval shaped tablets of 
F-11 with different compression forces was found to be 
maximum at 1 h in the range of 1073-1280%. As the time 
progress, tablets started to erode (Figure 9). The in vitro 
dissolution studies of formulation F-11 with hardness 2, 
3, 4, and 5 kg/cm2 were found to be 7.0, 7.2, 7.4 and 8.4 h 
at t90, respectively, whereas round tablet with hardness of 
5 kg/cm2, found to be 10.8 h at t90 (Figure 10).
Stability studies
The accelerated stability studies carried out for a 
duration of 3 months as per ICH guidelines indicated the 
best optimized formulation was stable. This was concluded 
following the evaluation of the formulation for physical 
appearance, drug content and drug release profile.
CONCLUSION
The present study was to design and develop novel 
in situ gel tablet of mercaptopurine for sustained drug 
delivery. By observing the low solubility problem and 
its erratic absorption throughout the GIT, an attempt was 
made to enhance drug absorption by making the drug 
release throughout the GIT. A systematic study using a 32 
full-factorial design revealed that by selecting a suitable 
composition of xanthan gum and sodium chloride, the 
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desired swelling index and release profile can be achieved. 
The best optimized formulation showed good swelling 
index and extended the release up to 12h. Further in vivo 
investigations may prove the possibility of improvement 
in the oral bioavailability of the mercaptopurine as an in 
situ gel tablet.
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